Carrie House, PhDSan Diego State University Research FoundationSan Diego, CA Role of Macrophages in the Development of Drug-Resistant Ovarian Cancer Stem Cells Following Chemotherapy Ovarian cancer is the deadliest gynecological cancer in the United States and is associated with a high rate of recurrence. Unfortunately, tumors that grow back stop responding to chemotherapy and become […]
Read More
Ilana Chefetz, PhDUniversity of Minnesota – Twin Cities2020 Lynda’s Fund Pilot Study Award AMPK-alpha-like proteins in a high grade serous ovarian cancer Although epithelial ovarian cancer responds well to initial treatment, the cancer recurs in a significant number of women. Once ovarian cancer recurs it is generally lethal, with fewer than 10% of patients surviving […]
Read More
Rosemary Foster, PhDMassachusetts General Hospital Identification and Characterization of the Ovarian Cancer Stem Cell Cancer stem cells have recently been identified in some solid tumors and are thought to drive tumor formation. Most tumors likely contain rare subpopulations of stem-like cells that would serve as critical targets of more clinically effective therapies. Our research experiments […]
Read More
Fiona Simpkins, MDUniversity of Miami Characterization of Subpopulations Capable of Self-Renewal in Ovarian Cancers Most ovarian cancer patients suffer disease recurrence, and most available chemotherapies are toxic and stop working. Cancer stem cells comprise a subpopulation of cells capable of self-renewal and are resistant to chemotherapy. By characterizing such subpopulations and determining which signaling pathways […]
Read More
Andre Lieber, MD, PhDFred Hutchinson Cancer Research Center Clonality Analysis in Ovarian Cancer In preliminary studies, Dr. Lieber’s laboratory has identified new markers for ovarian cancer ovca stem cells. In this new study, his team will continue to address the concept of ovarian cancer stem cells and the phenotypic plasticity of ovarian cancer cells. Dr. […]
Read More
Daniela Dinulescu, PhDBrigham and Women’s Hospital Nanotechology-based Therapy Targeting Platinum Resistant Disease An exciting new hypothesis in ovarian cancer biology is that tumor development is driven by cancer stem cells, which are resistant to standard chemotherapies and consequently responsible for the high rate of tumor relapse seen in patients. Animal models, which accurately recapitulate the […]
Read More
Resham Bhattacharya, PhDMayo Clinic Therapeutic targeting of Bmi-1 in ovarian cancer While platinum-based drugs continue to be the foundation of therapy for ovarian cancer, chemoresistance remains the main challenge for effective management of recurrent disease. The development of new therapeutic strategies to combat ovarian cancer is needed. This study will examine the therapeutic potential of […]
Read More
Alexander Nikitin, MD, PhDCornell University Role of Stem Cells in Ovarian Cancer Understanding of epithelial ovarian cancer development is critical for designing effective diagnostic and therapeutic approaches. During recent years it has become increasingly clear that cancers may arise from stem and progenitor cells. However, the location of the stem cell compartment of the ovarian […]
Read More
Geeta Mehta, PhDUniversity of Michigan Shear stress modulates invasiveness, tumorigenicity, and immune responses in ovarian stem cells The ovarian cancer environment in the abdominal cavity is quite complex, as cancer cells exist among cancer progenitor cells and immune cells in the ascites fluid. The physical stress from fluid movement and interactions with other cells likely […]
Read More
Angela Russo, Ph.DUniversity of Illinois at Chicago – UICChicago, IL, United States2018 MARLYS CHENEY PILOT AWARD Project: Characterization and targeting the markers of stemness altered during ovarian cancer pathogenesis using WNT inhibitors Research Areas: Cell Biology, Stem Cells, Tumor Microenvironment Summary:High-grade serous ovarian cancer is the most common type of ovarian cancer with the highest mortality rate. […]
Read More